NATCO, the underperforming quality pharma stockInvestors are wary of Natco Pharma as it has failed to perform in earlier years when it was tipped to be the one. However, the fundamentals are painting a different picture, with a sublime Q4 performance, USFDA approval of its Vizag unit, drug launch approvals in US, subsidiaries in Canada and Mexico doing well, the seguey into agrochemicals stabilizing....negligible debt, competed a 2% buyback in May 2023 wherein the promoters did not participate.. it has a modest PE valuation as on date compared to its 5 year history... stock has already broken out of its downtrend... a bit of consolidation is alway good before further direction emerges.. keeping a stoploss of 609 I am taking position in this counter
